CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023

Dec 19, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-15

Reporting Person: Harper Molly (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-15	Common stock, par value $0.001 per share	S	4000	$14.43	Disposed	0	Direct
2023-12-15	Common stock, par value $0.001 per share	M	10000	$5.78	Acquired	10000	Direct
2023-12-15	Common stock, par value $0.001 per share	S	10000	$14.37	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-15	Options to purchase common stock	$5.78	M	10000	Disposed	2028-06-29	Common Stock (10000)	Direct

Footnotes

F1: Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.

F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $14.37 to $14.40 per share.

F3: Options vest in three annual tranches beginning on June 29, 2022.